Atricure Stock Today
| ATRC Stock | USD 31.80 1.10 3.34% |
PerformanceWeakest
| Odds Of DistressLow
|
AtriCure is trading at 31.80 as of the 13th of February 2026, a 3.34 percent decrease since the beginning of the trading day. The stock's open price was 32.9. AtriCure has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 15th of November 2025 and ending today, the 13th of February 2026. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 5th of August 2005 | Category Healthcare | Classification Health Care |
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company was incorporated in 2000 and is headquartered in Mason, Ohio. The company has 49.72 M outstanding shares of which 2.51 M shares are presently shorted by private and institutional investors with about 4.92 trading days to cover. More on AtriCure
Moving against AtriCure Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
AtriCure Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO and President and Director | Michael Carrel | ||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsBy employing borrowed capital, AtriCure can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on AtriCure's use of financial leverage and reveals what portion of AtriCure's asset base relies on creditor financing.
| |||||
AtriCure (ATRC) is traded on NASDAQ Exchange in USA and employs 1,300 people. AtriCure is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.58 B. AtriCure conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 49.72 M outstanding shares of which 2.51 M shares are presently shorted by private and institutional investors with about 4.92 trading days to cover.
AtriCure currently holds about 118.45 M in cash with 12.2 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.55.
Check AtriCure Probability Of Bankruptcy
Ownership AllocationThe majority of AtriCure outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in AtriCure to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in AtriCure. Please pay attention to any change in the institutional holdings of AtriCure as this could imply that something significant has changed or is about to change at the company.
Check AtriCure Ownership Details
AtriCure Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| First Light Asset Management, Llc | 2025-06-30 | 1 M | |
| Gw&k Investment Management, Llc | 2025-06-30 | 1 M | |
| Marshall Wace Asset Management Ltd | 2025-06-30 | 1 M | |
| Nuveen, Llc | 2025-06-30 | 938.2 K | |
| Dimensional Fund Advisors, Inc. | 2025-06-30 | 820.1 K | |
| Bnp Paribas Investment Partners Sa | 2025-06-30 | 755.5 K | |
| Goldman Sachs Group Inc | 2025-06-30 | 745 K | |
| Ing Investment Management Llc | 2025-06-30 | 710.4 K | |
| Bank Of America Corp | 2025-06-30 | 710.2 K | |
| Vanguard Group Inc | 2025-06-30 | 4.9 M | |
| Blackrock Inc | 2025-06-30 | 4 M |
AtriCure Historical Income Statement
AtriCure Stock Against Markets
AtriCure Corporate Management
| Deborah Yount | Chief Officer | Profile | |
| Tonya SPHR | VP HR | Profile | |
| Vinayak Doraiswamy | Chief Officer | Profile | |
| JD CCEP | Chief Officer | Profile | |
| Salvatore JD | Chief Officer | Profile | |
| CCEP CCEP | Chief Officer | Profile |
Already Invested in AtriCure?
The danger of trading AtriCure is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AtriCure is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AtriCure. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AtriCure is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AtriCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AtriCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atricure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atricure Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Will Health Care Equipment & Supplies sector continue expanding? Could AtriCure diversify its offerings? Factors like these will boost the valuation of AtriCure. If investors know AtriCure will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AtriCure data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.59) | Revenue Per Share | Quarterly Revenue Growth 0.158 | Return On Assets | Return On Equity |
Understanding AtriCure requires distinguishing between market price and book value, where the latter reflects AtriCure's accounting equity. The concept of intrinsic value - what AtriCure's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push AtriCure's price substantially above or below its fundamental value.
Understanding that AtriCure's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AtriCure represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, AtriCure's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.